Changchun High-Tech subsidiary gets clinical trial approval for carbergoline
Changchun High & New Technology Industry Group announced its subsidiary GeneScience Pharmaceutical received National Medical Products Administration approval for clinical trials of domestically produced Carbergoline Tablets.
The drug treats hyperprolactinemia and pituitary prolactinoma as a dopamine D2 receptor agonist. It's positioned as a replacement for bromocriptine, offering stronger prolactin inhibition with fewer side effects over longer duration.
No similar products currently exist on the domestic market.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Changchun High & New Technology Industry Group publishes news
Free account required • Unsubscribe anytime